Events & Presentations

Investors

Events & Presentations

Upcoming Events
More events are coming soon.
Archived Events
Date Event Details
Nov 13, 2018
30th EORTC-NCI-AACR Symposium
Dublin
November 13, 10:00 a.m. GMT – Dr. Given will deliver a poster presentation titled, “Targeting HIF2α with an RNAi therapeutic for the treatment of clear cell renal cell carcinoma”
Nov 12, 2018
American Heart Association Scientific Sessions 2018
Chicago
November 12, 10:45 a.m. CST – Rui Zhu, Ph.D., Arrowhead’s senior chemist, will deliver an oral presentation titled, “RNA Interference Mediated Apolipoprotein C3 Gene Silencing as a Therapeutic for Hypertriglyceridemia”

November 12, 11:45 a.m. CST – So Wong, Ph.D., Arrowhead’s director of oncology, will deliver an oral presentation titled, “Development of an RNA Interference Therapeutic Targeting Angiopoietin-Like Protein 3 for Treatment of Hyperlipidemia”
Nov 12, 2018
The Liver Meeting® 2018, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD)

First Results with RNA interference (RNAi) in Chronic Hepatitis B (CHB) Using ARO-HBV

  • Publication Number: LB-25
  • Session: Late-Breaking Poster Session
  • Session Date and Time: November 12, 2018 from 8:00 AM to 5:30 PM PT
  • Location: Moscone Center North/South Building, Hall C
  • Authors: Dr. Edward J. Gane, et al.


A Phase 1 Single and Multiple Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Effect of ARO-AAT on Serum Alpha-1 Antitrypsin levels in Normal Adult Volunteers

  • Publication Number: LB-9
  • Session: Late-Breaking Poster Session
  • Session Date and Time: November 12, 2018 from 8:00 AM to 5:30 PM PT
  • Location: Moscone Center North/South Building, Hall C
  • Authors: Dr. Christian Schwabe, et al.
Nov 9, 2018
The Search for HBV / HDV Cure: Challenges for Industry
San Francisco
November 9, 11:15 a.m. PST – Dr. Given will deliver an oral presentation titled, “AROHBV1001 Results Update”
Nov 7, 2018
International HBV Cure Workshop 2018
Toronto
November 7, 3:35 p.m. EST – Bruce Given, M.D., Arrowhead’s chief operating officer, will deliver an oral presentation titled, “Clinical update on reducing HBV virus and antigen production using RNAi”
Nov 6, 2018
BIT’s 16th Annual Congress of International Drug Discovery Science and Technology
Jinan, China
November 6, 11:20 a.m. CST – Zhen Li, Ph.D., Arrowhead’s senior vice president of chemistry and non-clinical development, will deliver a keynote presentation titled, “Discovery and Development of Arrowhead Clinical Candidates ARO-AAT and ARO-HBV”
Oct 18, 2018 11:15 AM MDT
North American Cystic Fibrosis Conference
Denver, CO
Erik Bush, Ph.D., Arrowhead’s director of extra-hepatic targeting, will deliver a poster presentation titled, “A novel targeted RNAi molecule (TRiM™) delivery platform for the therapeutic inhibition of ENaC in cystic fibrosis lung disease”
Oct 16, 2018 1:00 PM EDT
Arrowhead Analyst R&D Day 2018
New York, NY
Arrowhead management and external key opinion leaders will discuss Arrowhead’s emerging pipeline of RNAi therapeutics
Oct 9, 2018 1:00 PM EDT
Chardan 2nd Annual Genetic Medicines Conference
New York, NY
Bruce Given, M.D., Arrowhead’s chief operating officer, will participate in a fireside chat.
Oct 5, 2018 7:00 AM EDT
2018 International HBV Meeting - The Molecular Biology of Hepatitis B
Taormina, Italy
October 5, 1:00 p.m. CEST –Christine Wooddell, Ph.D., Arrowhead’s director of liver targeting, will deliver a poster presentation titled, “Gene expression analysis during and after RNAi treatment of chronically HBV infected chimpanzees”